The present invention relates to a compound selected from these of formula (I): ##STR1## in which A and R.sub.1 are as defined in the description, and medicinal product containing the same which is useful for treating a disorder linked to the 5-HT.sub.3 receptors.
La présente invention concerne les composés de formule (I) :
dans laquelle A et R₁ sont tels que définis dans la description.
Médicaments.
本发明涉及式(I)化合物:
其中 A 和 R₁ 如描述中所定义。
药物。
Novel and Selective Partial Agonists of 5-HT<sub>3</sub> Receptors. 2. Synthesis and Biological Evaluation of Piperazinopyridopyrrolopyrazines, Piperazinopyrroloquinoxalines, and Piperazinopyridopyrroloquinoxalines
In continuation of our previous work on piperazinopyrrolothienopyrazine derivatives, three series of piperazinopyridopyrrolopyrazines, piperazinopyrroloquinoxalines, and piperazinopyridopyrrolaquinoxalines were prepared and evaluated as 5-HT3 receptor ligands. The chemical modifications performed within these new series led to structure-activity relationships regarding both high affinity and selectivity for the 5-HT3 receptors that are in agreement with those established previously for the pyrrolothienopyrazine series. The best compound (8a) obtained in these new series is in the picomolar range of affinity for 5-HT3 receptors with a selectivity higher than 10(6). Four of the high-affinity 5-HT3 ligands (8a, 15a,b, and 16d) were selected in both the pyridopyrrolopyrazine and the pyrroloquinoxaline series and were characterized in vitro and in vivo as agonists or partial agonists. Compound 8a was also evaluated in the light/dark test where it showed potential anxiolytic-like activity at very low doses per os.
LANCELOT, JEAN-CHARLES;ROBBA, MAX;DUNG, NGUYEN HUY;VIOSSAT, BERNARD, CHEM. AND PHARM. BULL., 36,(1988) N 9, C. 3248-3252
作者:LANCELOT, JEAN-CHARLES、ROBBA, MAX、DUNG, NGUYEN HUY、VIOSSAT, BERNARD